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Abstract 
 
Recently, we reported that intracerebroventricularly 
(i.c.v.) administered histamine evokes the secretion of 
noradrenaline and adrenaline from adrenal medulla by brain 
cyclooxygenase-1- and thromboxane A2-mediated mechanisms in 
rats. These results suggest the involvement of brain 
arachidonic acid cascade in the histamine-induced activation 
of the central adrenomedullary outflow. Arachidonic acid is 
released mainly by phospholipase A2 (PLA2)-dependent pathway 
or phospholipase C (PLC)/diacylglycerol lipase-dependent 
pathway. In the present study, histamine (27 nmol/animal, 
i.c.v.)-induced elevation of plasma noradrenaline and 
adrenaline was dose-dependently reduced by U-73122 (PLC 
inhibitor) (10 and 100 nmol/animal, i.c.v.), ET-18-OCH3 
(phosphatidylinositol-specific PLC inhibitor) (10 and 30 
nmol/animal, i.c.v.) and RHC-80267 (diacylglycerol lipase 
inhibitor) (1.3 and 2.6 µmol/animal, i.c.v.). However, 
mepacrine (PLA2 inhibitor) (1.1 and 2.2 µmol/animal, i.c.v.) 
and D609 (phosphatidylcholine-specific PLC inhibitor) (30, 
100 and 300 nmol/animal, i.c.v.) had no effect. These 
results suggest the involvement of brain 
phosphatidylinositol-specific PLC and diacylglycerol lipase 
in the centrally administered histamine-induced activation 
of the adrenomedullary outflow in rats.    
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1.  Introduction 
 
Oxygenated metabolites of arachidonic acid such as 
prostaglandins and thromboxane A2 have been demonstrated to 
act as neuromediator and/or neuromodulator in the brain 
actions including cardiovascular function (Chiu and 
Richardson, 1983; Wood et al., 1993; Zhang et al., 2003) 
and regulation of hormone secretion (Brooks et al., 1986; 
Bernardini et al., 1989; Reimsnider and Wood, 2006). 
Previously, we reported the involvement of brain 
arachidonic acid cascade in the centrally administered 
corticotropin-releasing factor-, arginine-vasopressin- and 
bombesin-induced elevation of plasma noradrenaline and 
adrenaline, since these responses were attenuated by 
central pretreatment with indomethacin, an inhibitor of 
cyclooxygenase, in rats (Okuma et al., 1997; Okada et al., 
2003b). In addition, centrally administered arachidonic 
acid elevated plasma levels of both catecholamines and 
these elevations were attenuated by central pretreatment 
with indomethacin in rats (Yokotani et al., 2000). These 
results suggest the involvement of active metabolites of 
brain arachidonic acid in activation of the central 
sympatho-adrenomedullary outflow in rats. 
Arachidonic acid has been shown to be released mainly 
by two different pathways: (1) phospholipase A2 (PLA2) 
hydrolyzes the sn-2 ester bond of membrane phospholipids, 
thereby releasing arachidonic acid (Irvine, 1982; Balsinde 
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et al., 2002); (2) phospholipase C (PLC) cleaves the 
phosphodiester bond, resulting in the formation of 
diacylglycerol, which can be hydrolyzed by diacylglycerol 
lipase to yield arachidonic acid (Bell et al., 1979; Irvine, 
1982; Moscat et al., 1986; Hou et al., 1996; Tang et al., 
2006). Previously, we reported that the brain PLA2 is 
involved in the centrally administered melittin (PLA2 
activator)-induced elevation of plasma noradrenaline and 
adrenaline (Yokotani et al., 2000), and that the brain PLC-
diacylglycerol lipase pathway is involved in the centrally 
administered corticotropin-releasing factor-, arginine-
vasopressin- and bombesin-induced elevation of plasma 
catecholamines in rats (Okada et al., 2003b; Shimizu et al., 
2004, 2005).  
Recently, we reported that central pretreatment with 
ketoprofen, an inhibitor of cyclooxygenase-1, attenuated 
the centrally administered histamine-induced elevation of 
plasma noradrenaline and adrenaline in rats (Shimizu et al., 
2006). In the present experiment, therefore, we aimed to 
clarify which phospholipase is involved in the histamine-
induced elevation of plasma catecholamines using 
anesthetized rats. 
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2.  Materials and methods 
    
2.1.  Experimental procedures 
 
Male Wistar rats weighing about 350 g were maintained 
in an air-conditioned room at 22-24°C under a constant day-
night rhythm for more than 2 weeks and given food 
(laboratory chow, CE-2; Clea Japan, Hamamatsu, Japan) and 
water ad libitum. Under urethane anesthesia (1.2 g/kg, 
i.p.), the femoral vein was cannulated for infusion of 
saline (1.2 ml/h), and the femoral artery was cannulated 
for collecting blood samples. After these procedures, the 
animal was placed in a stereotaxic apparatus, as shown in 
our previous papers (Yokotani et al., 1995; Shimizu et al., 
2004). The skull was drilled for intracerebroventricular 
administration of test substances using stainless-steel 
cannula (0.3 mm outer diameter). The stereotaxic 
coordinates of the tip of cannula were as follows (in mm): 
AP -0.8, L 1.5, V 4.0 (AP, anterior from the bregma; L, 
lateral from the midline; V, below the surface of the 
brain), according to the rat brain atlas (Paxinos and 
Watson, 1986). Three hours were allowed to elapse before 
the application of histamine or the application of blocking 
reagents. 
Histamine dissolved in sterile saline was slowly 
injected into the right lateral ventricle in a volume of 10 
µl/animal using a 25-µl Hamilton syringe. Each animal 
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received only one dose of histamine (or vehicle). Mepacrine 
and tricyclodecane-9-yl xanthate potassium salt (D609) 
dissolved in sterile saline were intracerebroventricularly 
(i.c.v.) administered in a volume of 5 µl/animal using a 
10-µl Hamilton syringe. 1-[6-[[(17β)-3-Methoxyestra-
1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5-dione (U-
73122) and 1,6-bis(cyclohexyloximinocarbonylamino)hexane 
(RHC-80267) dissolved in 2.5 µl of 100% N,N-
dimethylformamide (DMF)/animal were i.c.v. administered 
using a 10-µl Hamilton syringe. 1-O-Octadecylinin-2-O-
methyl-sn-glycero-3-phosphorylcholine (ET-18-OCH3) dissolved 
in 100% DMF was i.c.v. administered using a 10-µl Hamilton 
syringe in a volume of 5 µl/animal due to it's low 
solubility in DMF. In the case of using blocking reagents, 
histamine was i.c.v. administered 30 min after application 
of U-73122, RHC-80267, ET-18-OCH3 and D609, and 180 min 
after application of mepacrine due to their slightly 
elevating effects on the basal plasma levels of 
catecholamines. Each animal also received only one dose of 
blocking reagents (or vehicles). 
All experiments were conducted in compliance with the 
guiding principles for the care and use of laboratory 
animals approved by the Kochi University. 
   
2.2.  Measurement of plasma catecholamines 
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Blood samples (250 µl) were collected through an 
arterial catheter and were preserved on ice during 
experiments. Plasma were prepared immediately after the 
final sampling. Catecholamines in the plasma were extracted 
by the method of Anton and Sayre (1962) with a slight 
modification and were assayed electrochemically with high 
performance liquid chromatography (HPLC) (Shimizu et al., 
2004). Briefly, after centrifugation, the plasma (100 µl) 
was transferred to a centrifuge tube containing 30 mg of 
activated alumina, 2 ml of double deionized water, 1 ml of 
1.5 M Tris Buffer (pH 8.6) containing 0.1 M disodium EDTA 
and 1 ng of 3,4-dihydroxybenzylamine as an internal 
standard. The tube was shaken for 10 min and the alumina 
was washed three times with 4 ml of ice-cold double 
deionized water. Then, catecholamines adsorbed onto the 
alumina were eluted with 300 µl of 4% acetic acid 
containing 0.1 mM disodium EDTA. A pump (EP-300: Eicom, 
Kyoto, Japan), a sample injector (Model-231XL; Gilson, 
Villiers-le-Bel, France) and an electrochemical detector 
(ECD-300: Eicom) equipped with a graphite electrode were 
used with HPLC. Analytical conditions were as follows: 
detector, +450 mV potential against a Ag/AgCl reference 
electrode; column, Eicompack CA-50DS, 2.1 x 150 mm (Eicom); 
mobile phase, 0.1 M NaH2PO4-Na2HPO4 buffer (pH 6.0) 
containing 50 mg/l EDTA dihydrate, 0.75 g/l sodium 1-
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octanesulfonate and 15% methanol at a flow of 0.18 ml/min; 
injection volume, 40 µl. The amount of catecholamines in 
each sample was calculated using the peak height ratio 
relative to that of 3,4-dihydroxybenzylamine. By this assay, 
coefficients of variation for intra- and inter-assay were 
3.0% and 3.7%, respectively, and 0.5 pg of noradrenaline 
and adrenaline were accurately determined. 
 
2.3.  Treatment of data and statistics  
  
All values are expressed as the means±S.E.M. The data 
were analyzed by repeated-measure analysis of variance, 
followed by post-hoc analysis with the Bonferroni method. P 
values less than 0.05 were taken to indicate statistical 
significance. 
 
2.4.  Compounds  
 
The following drugs were used: mepacrine (quinacrine) 
dihydrochloride (Research Biochemicals, Natik, MA, USA); U-
73122, RHC-80267 and D609 (Biomol Research Lab., Plymouth 
Meeting, PA, USA); ET-18-OCH3 (Sigma Aldorich Fine Chemicals, 
St. Louis, MO, U.S.A.). Histamine dihydrochloride and all 
other reagents were the highest grade available (Nacalai 
Tesque, Kyoto, Japan). 
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3.  Results 
 
3.1.  Effect of mepacrine (an inhibitor of PLA2) on the 
centrally administered histamine-induced elevation of 
plasma catecholamines   
 
Treatments with vehicle-1 (5 µl saline/animal, i.c.v.) 
and vehicle-2 (10 µl saline/animal, i.c.v.) had no effect 
on the basal plasma levels of noradrenaline and adrenaline 
(Fig. 1). Pretreatment with mepacrine [2.2 µmol (1000 
µg)/animal, i.c.v.] also had no effect on the basal plasma 
levels of both catecholamines (Fig. 1). 
Since we previously reported that histamine [5.4, 27 
and 54 nmol (1, 5 and 10 µg)/animal, i.c.v.] dose-
dependently elevated plasma levels of both catecholamines 
(Shimizu et al., 2006), we used the dose of 27 nmol (5 
µg)/animal in the present experiment. Administration of 
histamine [27 nmol (5 µg)/animal, i.c.v.] rapidly increased 
plasma levels of noradrenaline and adrenaline. These 
responses reached a maximum 10 min after administration of 
histamine and then declined toward their basal levels (Fig. 
1). The histamine-induced elevation of both catecholamines 
was not influenced by mepacrine [1.1 and 2.2 µmol (500 and 
1000 µg)/animal, i.c.v.] (Fig. 1).  
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3.2.  Effect of U-73122 (an inhibitor of PLC) on the 
centrally administered histamine-induced elevation of 
plasma catecholamines   
 
Treatments with vehicle-1 (2.5 µl DMF/animal, i.c.v.)  
and vehicle-2 (10 µl saline/animal, i.c.v.) had no effect 
on the basal plasma levels of noradrenaline and adrenaline 
(Fig. 2). Pretreatment with U-73122 [100 nmol (46 
µg)/animal, i.c.v.] also had no effect on the basal plasma 
levels of both catecholamines (Fig. 2).  
The histamine [27 nmol (5 µg)/animal, i.c.v.]-induced 
elevation of both catecholamines was attenuated by U-73122 
in a dose-dependent manner [10 and 100 nmol (4.6 and 46 
µg)/animal, i.c.v.] (Fig. 2).    
 
3.3.  Effects of ET-18-OCH3 (an inhibitor of 
phosphatidylinositol-specific PLC) and D609 (an inhibitor 
of phosphatidylcholine-specific PLC) on the centrally 
administered histamine-induced elevation of plasma 
catecholamines  
 
Treatments with vehicle-1 (5 µl DMF or saline/animal, 
i.c.v.) and vehicle-2 (10 µl saline/animal, i.c.v.) had no 
effect on the basal plasma levels of noradrenaline and 
adrenaline (Fig. 3A and B). Pretreatment with ET-18-OCH3 [30 
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nmol (15.7 µg)/animal, i.c.v.] and D609 [300 nmol (80 
µg)/animal, i.c.v.] also had no effect on the basal plasma 
levels of both catecholamines (Fig. 3A and B).  
ET-18-OCH3 [10 and 30 nmol (5.2 and 15.7 µg)/animal, 
i.c.v.] dose-dependently reduced the histamine [27 nmol (5 
µg)/animal, i.c.v.]-induced elevation of plasma levels of 
noradrenaline and adrenaline (Fig. 3A). On the other hand, 
the histamine-induced response was not influenced by D609 
[30, 100 and 300 nmol (8, 27 and 80 µg)/animal, i.c.v.] 
(Fig. 3B).   
 
3.4.  Effect of RHC-80267 (an inhibitor of diacylglycerol 
lipase) on the centrally administered histamine-induced 
elevation of plasma catecholamines  
 
Treatments with vehicle-1 (2.5 µl DMF/animal, i.c.v.)  
and vehicle-2 (10 µl saline/animal, i.c.v.) had no effect 
on the basal plasma levels of noradrenaline and adrenaline 
(Fig. 4). Pretreatment with RHC-80267 [2.6 µmol (1000 
µg)/animal, i.c.v.] also had no effect on the basal plasma 
levels of both catecholamines (Fig. 4).  
The histamine [27 nmol (5 µg)/animal, i.c.v.]-induced 
elevation of both catecholamines was attenuated by RHC-
13 
80267 in a dose-dependent manner [1.3 and 2.6 µmol (500 and 
1000 µg)/animal, i.c.v.] (Fig. 4). 
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4.  Discussion 
 
PLA2 plays critical roles in the synthesis of 
arachidonic acid. To date, twelve groups of mammalian PLA2 
have been identified (Six and Dennis, 2000; Balsinde et al., 
2002). They are classified into two major categories, 
secreted PLA2 and cytosolic PLA2. Mepacrine (quinacrine) is 
widely used as a nonselective inhibitor of PLA2, thereby 
inhibiting both secreted PLA2 and cytosolic PLA2 (Fioretti 
et al., 2004; Hirose et al., 2007). Mepacrine has been 
shown to inhibit the release of arachidonic acid induced by 
N-methyl-D-aspartate at concentrations that inhibit PLA2 
activity, but not affect PLC activity, in primary culture 
of cerebellar granule cells (Lazarewicz et al., 1990). 
Mepacrine also blocks melittin (a PLA2 activator)-stimulated 
prostaglandin E2 release from renal cortex slices (Churchill 
et al., 1990). Previously we reported that central 
pretreatment with mepacrine (1.1 µmol/animal) abolished the 
centrally administered melittin-induced elevation of plasma 
noradrenaline and adrenaline in rats (Yokotani et al., 
2000). In the present experiment, however, central 
pretreatment with a large dose of mepacrine (2.2 
µmol/animal) was ineffective on the centrally administered 
histamine-induced elevation of plasma catecholamines, 
although the responses evoked by histamine was much smaller 
than those evoked by melittin. The result suggests the 
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involvement of the other phospholipase than PLA2 in the 
histamine-induced elevation of plasma catecholamines in 
rats. 
Arachidonic acid may also be released through PLC- and 
diacylglycerol lipase-mediated pathway. This pathway was 
reported to be a source of arachidonic acid in human 
platelets (Bell et al., 1979), murine macrophages (Moscat 
et al., 1986), rat pancreatic acini (Hou et al. 1996) and 
rabbit aortae  (Tang et al., 2006). U-73122 has been shown 
to be a selective inhibitor of PLC in human platelets and 
polymorphonuclear neutrophils (Bleasdale et al., 1990; 
Smith et al., 1990) and to antagonize the hyperalgesia 
evoked by histamine H1 receptor agonist [2-(3-
trifluoromethylphenyl)histamine]-induced activation of 
brain PLC in mice (Galeotti et al., 2004). In the present 
experiment, central pretreatment with U-73122 effectively 
reduced the centrally administered histamine-induced 
elevation of plasma catecholamines. The result suggests the 
involvement of the brain PLC in the histamine-induced 
elevation of plasma catecholamines in rats.  
There are two types of PLCs: phosphatidylinositol-
specific PLC and phosphatidylcholine-specific PLC. 
Phosphatidylinositol-specific PLC hydrolyzes 
phosphatidylinositol phosphate(s) and phosphatidylcholine-
specific PLC hydrolyzes phosphatidylcholine, thereby both 
generating diacylglycerol. The source of early production 
of diacylglycerol has been shown to be exclusively mediated 
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by phosphatidylinositol-specific PLC, while 
phosphatidylcholine is the source of the sustained 
production of diacylglycerol by phosphatidylcholine-
specific PLC (Diaz-Meco et al., 1989; Exton, 1994; Sbrissa 
et al., 1998; Rebecchi and Pentyala, 2000). Histamine has 
been reported to contract cat duodenal smooth muscle cells 
by phosphatidylinositol-specific PLC-mediated mechanisms 
(Jeong et al., 2003), and also to evoke Ca2+ current in 
guinea-pig ileal smooth muscle cells by 
phosphatidylcholine-specific PLC-mediated mechanisms (Unno 
et al., 1998). Then, we examined which PLC is involved in 
the centrally administered histamine-induced elevation of 
plasma catecholamines using ET-18-OCH3 and D609. ET-18-OCH3 
has been shown to selectively inhibit phosphatidylinositol-
specific PLC with an IC50 value of 9.6 µM in fibroblasts and 
adenocarcinoma cells (Powis et al., 1992). D609 selectively 
inhibits phosphatidylcholine-specific PLC with an IC50 value 
of 94 µM in human monocytic cells (Schutze et al., 1992). 
In the present experiment, central pretreatment with ET-18-
OCH3 (30 nmol/animal) effectively reduced the centrally 
administered histamine-induced elevation of plasma 
catecholamines, while central pretreatment with D609 was 
even ineffective on the histamine-induced responses at 
doses up to 300 nmol/animal. These results suggest the 
involvement of the brain phosphatidylinositol-specific PLC 
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in the histamine-induced elevation of plasma catecholamines 
in rats.   
Diacylglycerol can be hydrolyzed by diacylglycerol 
lipase to yield arachidonic acid. Diacylglycerol, produced 
by phosphatidylinositol-specific PLC from 
phosphatidylinositol phosphate(s), may function as an 
important cellular source of arachidonic acid. Tang et al. 
reported that the methacholine treatment of cultured rabbit 
aortic endothelial cells labeled with [14C] arachidonic acid 
results in the release of free [14C] arachidonic acid and in 
the decrease in radioactivity in phosphatidylinositol and 
diacylglycerol fractions of these cells (Tang et al., 2006). 
Furthermore, these responses induced by methacholine 
treatment were inhibited by U-73122 and RHC-80267, a 
selective inhibitor of diacylglycerol lipase (Levasseur et 
al., 1984; Natarajan et al., 1988). In the present 
experiment, central pretreatment with RHC-80267 effectively 
reduced the centrally administered histamine-induced 
elevation of plasma catecholamines, suggesting the 
involvement of brain diacylglycerol lipase in the 
histamine-induced elevation of plasma catecholamines in 
rats. 
Phospholipase D (PLD) has also been reported to be 
involved in the production of arachidonic acid. PLD-derived 
phosphatidate is subsequently transformed by phosphatidate 
phosphohydrolase into diacylglycerol, which can be further 
converted to arachidonic acid (Hodgkin et al., 1998; 
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Carrasco and Merida, 2007). In fact, PLD-phosphatidate 
phosphohydrolase pathway was reported to be a source of 
diacylglycerol and arachidonic acid in rat osteoblast-like 
cells (Kaneki et al., 1998) and cultured vascular smooth 
muscle cells (Freeman, 2000). However, the major substrate 
of PLD is phosphatidylcholine, which contains relatively 
little arachidonic acid in position 2 (Exton, 1994; Hodgkin 
et al., 1998; Carrasco and Merida, 2007). On the other hand, 
30-80% of total phosphatidylinositol is typically the sn-1-
stearoyl-2-arachidonyl species (Hodgkin et al., 1998; 
Carrasco and Merida, 2007). Other phospholipids such as 
phosphatidylserine and phosphatidylethanolamine can 
function as a source of arachidonic acid, however these 
phospholipids are preferentially hydrolyzed by PLA2 rather 
than PLC (Atsumi et al., 1997; Six and Dennis, 2000; 
Balsinde et al., 2002).  These observations suggest that the 
brain phosphatidylinositol-specific PLC rather than PLA2, 
phosphatidylcholine-specific PLC and PLD may metabolize 
mainly phosphatidylinositol phosphate(s) to diacylglycerol 
which functions as a source of arachidonic acid in response 
to the centrally administered histamine in rats. 
Previously, we reported that the centrally administered 
histamine-induced elevation of plasma catecholamines was 
attenuated by central pretreatment with ketoprofen, an 
inhibitor of cyclooxygenase-1, and furegrelate, an 
inhibitor of thromboxane A2 synthase, and also was abolished 
by bilateral adrenalectomy (Shimizu et al., 2006). These 
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results suggest that the brain arachidonic acid generated 
by histamine may be metabolized to thromboxane A2 by brain 
cyclooxygenase-1 and thromboxane A2 synthase, thereby 
evoking the secretion of noradrenaline and adrenaline from 
adrenal noradrenaline- and adrenaline-containing cells 
respectively in rats. The brain thromboxane A2-mediated 
secretion of noradrenaline and adrenaline from adrenal 
medulla was also demonstrated by centrally administered 
arginine-vasopressin and bombesin in rats (Okada et al., 
2003a; Yokotani et al., 2005).  
In summary, we demonstrated here that the centrally 
administered histamine activates the central 
adrenomedullary outflow by brain phosphatidylinositol-
specific PLC- and diacylglycerol lipase-dependent 
mechanisms, thereby increasing plasma levels of 
noradrenaline and adrenaline in rats. 
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Legends to figures 
 
Fig. 1.  Effect of mepacrine (an inhibitor of PLA2) on the 
centrally administered histamine-induced elevation of 
plasma catecholamines. ∆ Noradrenaline and ∆ Adrenaline: 
increments of noradrenaline and adrenaline above the basal. 
Mepacrine [1.1 and 2.2 µmol (500 and 1000 µg)/animal] or 
vehicle-1 (5 µl saline/animal) was 
intracerebroventricularly (i.c.v.) administered 180 min 
before the administration of histamine [27 nmol (5 
µg)/animal, i.c.v.] or vehicle-2 (10 µl saline/animal, 
i.c.v.). Arrows indicate the intracerebroventricular 
administrations of mepacrine/vehicle-1 and 
histamine/vehicle-2. Each point represents the mean±S.E.M. 
The actual values for noradrenaline and adrenaline at 0 min 
were 431±56 and 395±77 pg/ml in the group pretreated with 
vehicle-1 (n=10); 432±98 and 497±197 pg/ml in the group 
pretreated with mepacrine (1.1 µmol/animal) (n=5); 366±60 
and 474±107 pg/ml in the group pretreated with mepacrine 
(2.2 µmol/animal) (n=14), respectively.   
 
Fig. 2.  Effect of U-73122 (an inhibitor of PLC) on the 
centrally administered histamine-induced elevation of 
plasma catecholamines. U-73122 [10 and 100 nmol (4.6 and 46 
µg)/animal] or vehicle-1 (2.5 µl DMF/animal) was i.c.v. 
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administered 30 min before the administration of histamine 
[27 nmol (5 µg)/animal, i.c.v.] or vehicle-2 (10 µl 
saline/animal, i.c.v.). *p<0.05, significantly different 
from vehicle-1- and histamine-treated group. Other 
conditions were the same as those of Fig. 1. The actual 
values for noradrenaline and adrenaline at 0 min were 
305±33 and 223±36 pg/ml in the group pretreated with 
vehicle-1 (n=11); 354±85 and 391±164 pg/ml in the group 
pretreated with U-73122 (10 nmol/animal) (n=6); 323±59 and 
328±91 pg/ml in the group pretreated with U-73122 (100 
nmol/animal) (n=11), respectively. 
 
Fig. 3. Effects of ET-18-OCH3 (an inhibitor of 
phosphatidylinositol-specific PLC) and D609 (an inhibitor 
of phosphatidylcholine-specific PLC) on the centrally 
administered histamine-induced elevation of plasma 
catecholamines. (A) ET-18-OCH3 [10 and 30 nmol (5.2 and 15.7 
µg)/animal] or vehicle-1 (5 µl DMF/animal) was i.c.v. 
administered 30 min before the administration of histamine 
[27 nmol (5 µg)/animal, i.c.v.] or vehicle-2 (10 µl 
saline/animal, i.c.v.). *p<0.05, significantly different 
from vehicle-1- and histamine-treated group. Other 
conditions were the same as those of Figs. 1 and 2. The 
actual values for noradrenaline and adrenaline at 0 min 
were 335±34 and 211±38 pg/ml in the group pretreated with 
DMF (5 µl/animal) (n=13); 308±62 and 238±38 pg/ml in the 
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group pretreated with ET-18-OCH3 (10 nmol/animal) (n=6); 
357±75 and 261±54 pg/ml in the group pretreated with ET-18-
OCH3 (30 nmol/animal) (n=10), respectively. (B) D609 [30, 
100 and 300 nmol (8, 27 and 80 µg)/animal] or vehicle-1 (5 
µl saline/animal) was i.c.v. administered 30 min before the 
administration of histamine [27 nmol (5 µg)/animal, i.c.v.] 
or vehicle-2 (10 µl saline/animal, i.c.v.). Other 
conditions were the same as those of Figs. 1 and 2. The 
actual values for noradrenaline and adrenaline at 0 min 
were 370±60 and 350±87 pg/ml in the group pretreated with 
saline (5 µl/animal) (n=12); 397±144 and 319±173 pg/ml in 
the group pretreated with D609 (30 nmol/animal) (n=6); 
338±60 and 360±104 pg/ml in the group pretreated with D609 
(100 nmol/animal) (n=6); 380±66 and 377±64 pg/ml in the 
group pretreated with D609 (300 nmol/animal) (n=10), 
respectively. 
 
Fig. 4.  Effect of RHC-80267 (an inhibitor of diacylglycerol 
lipase) on the centrally administered histamine-induced 
elevation of plasma catecholamines. RHC-80267 [1.3 and 2.6 
µmol (500 and 1000 µg)/animal] or vehicle-1 (2.5 µl 
DMF/animal) was i.c.v. administered 30 min before the 
administration of histamine [27 nmol (5 µg)/animal, i.c.v.] 
or vehicle-2 (10 µl saline/animal, i.c.v.). *p<0.05, 
significantly different from vehicle-1- and histamine-
32 
treated group. Vehicle-1-treated groups were cited from Fig. 
2. Other conditions were the same as those of Figs. 1-3. 
The actual values for noradrenaline and adrenaline at 0 min 
were 213±24 and 347±80 pg/ml in the group pretreated with 
RHC-80267 (1.3 µmol/animal) (n=6); 214±39 and 268±102 pg/ml 
in the group pretreated with RHC-80267 (2.6 µmol/animal) 
(n=13), respectively. 
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